The patent entitled, ‘Transdermal Methods and Systems for the Delivery of Anti-Migraine Compounds,’ relates to methods of effectively treating a migraine using an iontophoretic patch containing a triptan.
Once issued, the patent will provide coverage for NuPathe’s lead product candidate, Zelrix, through April 2027.
Zelrix is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine.
NuPathe CEO Jane Hollingsworth said this important allowance further validates the novelty of their sumatriptan transdermal patch and represents yet another significant achievement for NuPathe as they advance towards the goal of providing a tolerable, non-oral treatment for migraine patients.
"The next milestone for NuPathe is our PDUFA date in August, which is the target date for the FDA to complete its review of our NDA for Zelrix," Hollingsworth said.